Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series

BACKGROUND: There is no standard treatment for stage III lung cancer due to its low surgical resection rate, and improving PFS and survival of patients with III NSCLC has become an urgent challenge in clinical treatment. For EGFR mutation-positive patients, targeted therapy has the remarkable featur...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Shao, Qiang, Zhang, Wanwan, Cheng, Zhaozhun, Zeng, Yuewu, Xie, Shencun, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004604/
https://www.ncbi.nlm.nih.gov/pubmed/35425698
http://dx.doi.org/10.3389/fonc.2022.872225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004604/
https://www.ncbi.nlm.nih.gov/pubmed/35425698
http://dx.doi.org/10.3389/fonc.2022.872225

Ejemplares similares